Search - tctmd.com

Displaying 441 - 460 of 486

Sort: Relevancy | Date

News Daily News

Nuevo Análisis PLATO: Las dosis de Aspirina podrían Explicar los Resultados Discordantes de Norteamérica

Caitlin E. Cox

March 06, 2012

News Daily News

New PLATO Analysis: Aspirin Dose May Explain Discordant North American Outcomes

Caitlin E. Cox

March 06, 2012

News Daily News

El mayor riesgo de episodios cerebrovasculares se da en las primeras 24 horas posteriores a un RVAT

March 06, 2012

News Daily News

Cerebrovascular Event Risk Highest in First 24 Hours After TAVR

March 06, 2012

News Daily News

Silent Cerebral Infarcts After Angiography Linked to Insufficient Platelet Inhibition

L.A. McKeown

January 12, 2012

News Conference News

Prasugrel Bests Double Clopidogrel Dose for STEMI Patients with High Residual Platelet Reactivity

November 17, 2011

News Conference News

AIDA STEMI: No Advantage for Intracoronary vs. Intravenous Abciximab

November 13, 2011

News Conference News

RAPID GENE: Validation of Point-of-Care Genetic Testing

November 09, 2011

News Conference News

PARIS: Early DAPT Nonadherence, A Small Problem with Big Consequences

November 09, 2011

News Industry News

Low CV Event Rate Prompts Closure of Prasugrel Trial

November 09, 2011

News Conference News

BRIDGE: Cangrelor Provides Effective Maintenance of Platelet Inhibition Without Major Bleeding

November 09, 2011

News Industry News

Tailored therapy for anti-platelet drugs using a novel point-of-care genetic test provides improved response to medications compared to current standard of care

November 08, 2011

News Industry News

First clinical trial of point-of-care DNA testing in medicine enables cardiac stent patients to receive personalized antiplatelet therapy

November 08, 2011

News Industry News

Clinical trial comparing Prasurgrel to Clopidogrel following percutaneous coronary intervention is ended early

November 08, 2011

News Conference News

Prasugrel, Ticagrelor Reduced Incidence of Stent Thrombosis

November 06, 2011

News Daily News

Thrombolysis with Immediate Transfer for PCI Safe for Rural STEMI Patients

November 02, 2011

News Industry News

Boston Scientific Announces Schedule of Events at TCT Scientific Symposium

November 01, 2011

News Daily News

First-Year Stent Thombosis Risk High—and Dangerous—in ACS Patients

October 31, 2011

News Daily News

High Platelet Reactivity Predicts Poor Outcomes, Routine Testing Still Debated

Jason Kahn

October 24, 2011

News Daily News

Bivalirudin Decreases Bleeding Regardless of Heparin Anticoagulation Level

Yael L. Maxwell

October 13, 2011

Advertisement

Nuevo Análisis PLATO: Las dosis de Aspirina podrían Explicar los Resultados Discordantes de Norteamérica

New PLATO Analysis: Aspirin Dose May Explain Discordant North American Outcomes

El mayor riesgo de episodios cerebrovasculares se da en las primeras 24 horas posteriores a un RVAT

Cerebrovascular Event Risk Highest in First 24 Hours After TAVR

Silent Cerebral Infarcts After Angiography Linked to Insufficient Platelet Inhibition

Prasugrel Bests Double Clopidogrel Dose for STEMI Patients with High Residual Platelet Reactivity

AIDA STEMI: No Advantage for Intracoronary vs. Intravenous Abciximab

RAPID GENE: Validation of Point-of-Care Genetic Testing

PARIS: Early DAPT Nonadherence, A Small Problem with Big Consequences

Low CV Event Rate Prompts Closure of Prasugrel Trial

BRIDGE: Cangrelor Provides Effective Maintenance of Platelet Inhibition Without Major Bleeding

Tailored therapy for anti-platelet drugs using a novel point-of-care genetic test provides improved response to medications compared to current standard of care

First clinical trial of point-of-care DNA testing in medicine enables cardiac stent patients to receive personalized antiplatelet therapy

Clinical trial comparing Prasurgrel to Clopidogrel following percutaneous coronary intervention is ended early

Prasugrel, Ticagrelor Reduced Incidence of Stent Thrombosis

Thrombolysis with Immediate Transfer for PCI Safe for Rural STEMI Patients

Boston Scientific Announces Schedule of Events at TCT Scientific Symposium

First-Year Stent Thombosis Risk High—and Dangerous—in ACS Patients

High Platelet Reactivity Predicts Poor Outcomes, Routine Testing Still Debated

Bivalirudin Decreases Bleeding Regardless of Heparin Anticoagulation Level

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content